Moxonidine: Pharmacology, clinical pharmacology and clinical profile

Blood Pressure

Volumn 7, Issue SUPPL. 3, 1998, Pages 23-27

  Elliott, Henry L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antihypertensive treatment; centrally acting; clinical profile; moxonidine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE;

BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DROWSINESS; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INSULIN SENSITIVITY; METABOLIC REGULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; XEROSTOMIA; REVIEW;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLES;

EID: 0032242647     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/080370598438447-1     Document Type: Article

References (20)

1. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD (ed.), Textbook of hypertension. Oxford: Blackwell, 1994: 1156-64.
2. 1) receptors as targets of centrally antihypertensives: moxonidine and rilmenidine. J Hypertens 1997; 15: 117-25. (Pubitemid 27116494)
3. Haxhiu MA, Dreshaj I, Ernsberger P. Central antihypertensive action of moxonidine: blockade by selective antagonists implicates I1-imidazoline receptors. J Pharmacol Exp Ther: submitted.
4. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-72.
5. Schafers RF, Phillip T. Moxonidine in hypertension treatment- a clinical summary. Cardiovasc Risk Factors 1995; 5: (Suppl 1): 45-54.
6. Prichard BNC, Graham BR. Effective antihypertensive therapy: blood pressure control with Moxonidine. J Cardiovasc Pharmacol 1996; (Suppl 3); 27: S38-48. (Pubitemid 26282651)
7. Kuppers HE, Jager BA, Luszick JH, Grave MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mildto- moderate essential hypertension. J Hypertens 1997; 15: 93-7. (Pubitemid 27075992)
8. Schrader J, et al. Moxonodine. A new centrally active antihypertensive drug. Internist (Berl). 1992; 33(10): 704-6.
9. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S45-9.
10. Frei M, Kuster L, Gardosch von Krosigk PP, Kosh HF, Kuppers H. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S25-8. (Pubitemid 24357073)
11. Division of Cardio-Renal Products, Food and Drug Administration Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Rockville, MD: USA Department of Health and Human Services, 1988.
12. Weimann H-J, Rudolph M. Clinical pharmacokinetics of moxonidine. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S37-41. (Pubitemid 23048806)
13. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27 Suppl 3: S49-54. (Pubitemid 26282652)
14. Schwarz W, Kandziora J. Langzeiterfahrungen mit Moxonidin, einem neuen antihypertensivum. Fortschr Med 1990; 32: 616-20.
15. Schmidt U, Frerick H, Kraft K, Schenk N, Low-Kroger A. Hypertension: a possible risk in road traffic. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S50-6. (Pubitemid 23048809)
16. Planitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-52. (Pubitemid 14007682)
17. Kaan EC, Bruckner R, Frohly P, et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 19-27.
18. Lithell H. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press 1998; 7 (Suppl 3): 28-31. (Pubitemid 29185403)
19. Eichstadt H, Richter W, Bader M, Cordes M, et al. Demonstration of hypertrophy: regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989; 3 (Suppl 2): 583.
20. Swedberg K. Inhibition of sympathetic nervous system activation in heart failure. Presentation at the XIXth Congress of the European Society of Cardiology, in Stockholm, Sweden. August 27, 1997.